Le Lézard
Classified in: Health, Science and technology, Covid-19 virus

InterMed Announces New InterAid Triage and Telemedicine Programs


ROCKLIN, Calif., July 13, 2020 /PRNewswire/ -- InterMed Cost Containment Services is excited to announce a new service offering to the risk management community. InterAid Triage and Telemedicine is a healthcare services platform that provides employers and their workers convenient alternative access to health services when physical access to a clinician is not possible or access to a healthcare professional is limited.

The InterAid Triage program affords injured workers and their employers to report incidents and seek medical advice quickly through a tool free hotline staffed by caring nurses 24/7. InterMed nurses provide a complete telephonic nursing assessment and clinical guidance using proven and evidence-based triage protocols. Our nurses can also prescribe approved over-the-counter medications under the direction of a Board-certified Medical Director with expertise in occupational injuries.

InterMed's telemedicine program incorporates innovative technology, clinical support, and a network of Board-certified healthcare providers carefully selected to provide care at a moment's notice using secure video conferencing systems that are compliant with the Health Insurance Portability and Accountability Act (HIPAA). Available 24/7, the program is designed to treat and facilitate assessment of a wide variety of workers' compensation injuries using evidence-based medicine.

In the current coronavirus pandemic, the telephonic triage and telemedicine programs reduce the risks associated with visiting a brick-and-mortar medical facility while providing early access to a clinician. The programs also provide employees a safe and convenient alternative to get information regarding possible COVID 19 exposures and receive answers to questions they may not want to ask their employers. "Our triage nurses are ready to field your employees' COVID 19 questions. InterMed is very proud to be able to support our clients during this pandemic with programs that can alleviate employees' coronavirus fears, regardless of exposure," said Jayne Miller, Senior Vice President of InterMed.

About InterMed Cost Containment Services

InterMed Cost Containment Services supports workers' compensation carriers and self-insured employers with a complete range of cost containment solutions that reduce medical costs while facilitating top quality care. Its advanced technology, integrated model, and experienced professionals collectively deliver quality outcomes and substantial savings.

Contact:

Jayne Miller
Senior VP Managed Care
916-780-3626
[email protected]

Laura Gannon
Director of Business Development
916-276-1822
[email protected]

SOURCE InterMed Cost Containment Services


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: